<DOC>
	<DOCNO>NCT00016198</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness combine fluorouracil leucovorin without oxaliplatin treat patient recurrent metastatic colorectal cancer .</brief_summary>
	<brief_title>Fluorouracil Leucovorin With Without Oxaliplatin Treating Patients With Recurrent Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall response rate overall survival patient recurrent metastatic colorectal adenocarcinoma treat third-line therapy comprise fluorouracil leucovorin calcium without oxaliplatin . II . Compare onset duration complete partial response duration disease stabilization patient treat regimen . III . Compare proportion patient stable disease proportion patient tumor-related symptomatic improvement treat regimen . IV . Compare time disease progression time tumor-related symptomatic worsening patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive leucovorin calcium IV 2 hour fluorouracil IV 2-4 minute follow fluorouracil IV continuously 22 hour day 1 2 . Arm II : Patients receive oxaliplatin IV 2 hour , leucovorin calcium IV 2 hour , fluorouracil IV 2-4 minute follow fluorouracil IV continuously 22 hour day 1 . On day 2 , patient receive leucovorin calcium fluorouracil arm I . Treatment arm repeat every 2 week least 1 year absence disease progression . Patients follow day 30 approximately 6 month . PROJECTED ACCRUAL : A total 200 patient ( 100 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma colon rectum Metastatic/recurrent disease amenable potentially curative therapy ( e.g. , inoperable metastatic disease ) Documented sequential disease progression ( CT scan MRI ) 2 prior chemotherapy regimens metastatic/recurrent disease At least 1 unidimensionally measurable lesion At least 20 mm conventional CT scan MRI OR At least 10 mm spiral CT scan Must receive prior fluorouracil ( capecitabine ) leucovorin calcium without irinotecan firstline therapy irinotecan without fluorouracil ( capecitabine ) leucovorin calcium secondline therapy metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN ( 6 time ULN document liver metastasis present ) Alkaline phosphatase great 2 time ULN ( 6 time ULN document liver metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV symptomatic congestive heart failure No serious cardiac arrhythmia No unstable angina No myocardial infarction within past 6 month Pulmonary : No interstitial pneumonia No extensive symptomatic fibrosis lung Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No known peripheral neuropathy ( absence deep tendon reflex sole neurologic abnormality allow ) No diabetes active infection No known dihydropyrimidine dehydrogenase deficiency PRIOR CONCURRENT THERAPY : Biologic therapy : No prior anticancer biologic therapy Chemotherapy : See Disease Characteristics No prior oxaliplatin No prior adjuvant irinotecan Prior adjuvant fluorouracil leucovorin calcium allow At least 3 week since prior chemotherapy ( e.g. , secondline irinotecan without fluorouracil ( capecitabine ) leucovorin calcium ) metastatic disease recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy No prior radiotherapy target lesion unless document progression within radiation portal Surgery : See Disease Characteristics At least 4 week since prior surgery primary tumor metastasis recover Other : No prior investigational anticancer drug No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>